

# How Might Lessons Learned from the U.S. Inform Regulatory Development in Other Countries?

Germana Barba, Vice President Regulatory Affairs Philip Morris International



# Global regulatory status

• E-cigarettes are effectively banned or face prohibitive medicinal licensing rules in over 30 countries







# Global regulatory status

- E-cigarettes are effectively banned or face prohibitive medicinal licensing rules in over 30 countries
- 40 countries have banned snus and/or other smokeless tobacco products







### Global regulatory status

- E-cigarettes are effectively banned or face prohibitive medicinal licensing rules in over 30 countries
- 40 countries have banned snus and/or other smokeless tobacco products
- Singapore bans all new tobacco and nicotine products







# WHO/FCTC guidance

- The WHO reported that there is insufficient evidence on the health impact of ENDS and on their effectiveness as a smoking cessation aid
- FCTC endorses regulatory measures "to prohibit or restrict the manufacture, importation, distribution, presentation, sale and use of ENDS/ENNDS"
  - Marketing bans or restrictions, bans on claims, indoor public use bans

Electronic Nicotine Delivery Systems and Electronic Non-Nicotine Delivery Systems (ENDS/ENNDS)

**Report by WHO** 





FCTC/COP7(9) Electronic nicotine delivery systems and electronic nonnicotine delivery systems

- WHO recommends all smokeless tobacco products, including emerging tobacco products should be regulated under the WHO FCTC
- WHO will monitor use of smokeless and novel tobacco products, assess the scientific data, and report to further COP sessions

#### Further development of the partial guidelines for implementation of Articles 9 and 10 of the WHO FCTC

Report by WHO

DECISION



FCTC/COP7(14) Further development of the partial guidelines for implementation of Articles 9 and 10 of the WHO FCTC (Regulation of the contents of tobacco products and







# Emerging policy model for tobacco and nicotine products



New policy models recognize that:

- The availability of lower risk products is an opportunity to reduce death and disease from smoking
- Harm reduction is a complement to other smoking prevention efforts
- Although nicotine is not benign, combustion is the bigger problem
- Innovative technologies can help minimize the risk of harm compared to cigarette smoking













# Translating policy into practice

Products should be allowed on the market	•	Standards for market access	NEW Product
Product, sales, marketing, usage and tax rules reflect the risk continuum, with heaviest restrictions applied to cigarettes	•	Encourages smokers to switch to less risky alternatives Drives manufacturers to invest and innovate	Japan Tobacco Looks to Invest S500m in Smokeless UI ELIQUID ELIQUID
Enable truthful and non- misleading information to consumers	•	Government communication initiatives Greater flexibility for consumer communication compared to cigarettes	

**FDLI** 

